The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0757 GMT - Germany's Merck KGaA reported a strong set of third-quarter results, with adjusted earnings beating expectations, which should help its shares when the market opens, J.P. Morgan analysts say in a research note. Quarterly sales were 2% ahead of consensus expectations and Ebitda before exceptional items beat forecasts by 7%, the analysts say. Both at the top and bottom lines, the performance of Merck's electronics business is the main driver the better-than-expected results, JPM says. The company also tightened its full-year guidance ranges. This, together with the better-than-forecast results, could lead to small upgrades to consensus expectations and to shares outperforming, the analysts say. (adria.calatayud@wsj.com)

0634 GMT - Biocon's resilient momentum in biosimilars is likely driving growth, Axis Securities' Aman Goyal says in a research report. Its 2Q FY 2026 revenue climbed 9% on-quarter, thanks to strong traction in biosimilars and generics, the analyst says. Management expects strong double-digit revenue growth in FY 2026, driven by sustained momentum in biosimilars, margin recovery in generics from 2H, and steady growth in the contract research, development and manufacturing organization segment, Goyal notes. The Indian biopharma company has also substantially strengthened its balance sheet by settling structured debt obligations. The brokerage raises the stock's target price to INR450.00 from INR380.00 and keeps a buy rating. Shares are 3.5% higher at INR420.75. (ronnie.harui@wsj.com)

0303 GMT - Riverstone's earnings could be weighed by persistent glove oversupply, say Nomura's Heng Siong Kong and Aakash Kedia in a note. The Singapore-listed glove manufacturer noted new production capacities are coming up in Indonesia, Cambodia and Vietnam as Chinese glove makers attempt to circumvent U.S. tariffs. Riverstone has also found it difficult to compete on glove pricing after Indonesia allowed coal use in production, the analysts add. They cut their 2025, 2026, and 2027 earnings per share estimates by 21%, 19% and 22%, respectively, to reflect slower volume growth and average selling price recovery, in line with Riverstone's more cautious outlook amid U.S. tariff uncertainty. Nomura lowers its rating to neutral from buy and trims the target to S$0.78 from S$0.93. The stock is down 0.6% at S$0.855.(megan.cheah@wsj.com)

1514 GMT - The Financial Accounting Standards Board votes to explore simplifying how companies report investments in other entities in which they have significant interests but not control. The board says it will add a project to its standard-setting agenda on the so-called equity method in response to feedback. Companies such as Eli Lilly and Block have sought changes to the rules, saying the equity method poses administrative costs and operational challenges. Investors have said they value the current method. "If anything, I think it calls into question why we permit the fair-value option for equity method investments, particularly when the securities aren't traded in the market," FASB Chair Rich Jones says. The FASB also decides not to add a project on renewable energy partnership accounting to its agenda. (mark.maurer@wsj.com; @markgmaurer)

1115 GMT - Strong results for Bayer's crop science segment helped offset a guidance cut for its consumer-health unit, JPMorgan analysts write in a note. A decline in the costs of goods sold, improved spending efficiencies and lower-than-expected reconciliation costs also supported the generally strong third quarter, the bank says. The German healthcare-and-agriculture company's significant exposure to challenging markets in the U.S. and China undercut consumer-health performance and contributed to the weaker outlook, Chief Financial Officer Wolfgang Nickl said in a call following the results. Shares rise 4.5% to trade at 28.67 euros. (william.gray@wsj.com)

(END) Dow Jones Newswires

November 13, 2025 04:20 ET (09:20 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.